Organon’s quarter was a mixed bag

The headline: not exactly a champagne quarter

Organon said first-quarter 2026 revenue came in at $1.46 billion, down from $1.513 billion a year ago. That’s not a disaster, but it’s also not the kind of number that makes Wall Street start doing cartwheels.

The good, the bad, and the biologics

The company’s Biosimilars business was the bright spot, climbing to $173 million from $141 million last year. That’s the part of the story investors will probably circle in neon marker, because it shows one engine is still running.

But the softer stuff mattered more:

• Women’s Health revenue dropped to $389 million from $463 million
• Established Brands was basically flat at $880 million versus $887 million
• Other revenue slipped to $18 million from $22 million

So yes, there were pockets of growth. But the overall picture still looks a bit like a treadmill: the company is moving, just not especially fast.

Why you should care

For investors, the question isn’t just whether Organon can report a decent quarter — it’s whether the mix keeps improving enough to offset the weaker legacy businesses. Biosimilars are doing their job. The rest of the portfolio? Less impressive.

Big picture

This looks like a company still trying to prove its growth story has enough legs to outrun its slower-moving pieces. In other words: the biosimilar spark is real, but the engine still needs more than one cylinder.